These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 18433304

  • 1. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration.
    Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, Frisina N, Lubrano C, Bonaiuto M, D'Anna R, Cannata ML, Corrado F, Cancellieri F, Faraci M, Marini R, Adamo EB, Wilson S, Squadrito F.
    J Bone Miner Res; 2008 May; 23(5):715-20. PubMed ID: 18433304
    [Abstract] [Full Text] [Related]

  • 2. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 May; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 3. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 May; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 4. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
    Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, Inferrera MA, Marini H, Bitto A, D'Anna R, Corrado F, Bartolone S, Frisina N, Squadrito F.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):188-92. PubMed ID: 14715848
    [Abstract] [Full Text] [Related]

  • 5. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009 Jan; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 6. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 7. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoğlu O.
    Nephron Clin Pract; 2007 Dec; 105(4):c153-8. PubMed ID: 17259742
    [Abstract] [Full Text] [Related]

  • 8. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [Abstract] [Full Text] [Related]

  • 9. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA, Mohamed NA, El-Metwally TH, Kamal MM.
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [Abstract] [Full Text] [Related]

  • 10. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction.
    Briana DD, Boutsikou M, Baka S, Hassiakos D, Gourgiotis D, Malamitsi-Puchner A.
    Neonatology; 2009 May; 96(2):132-6. PubMed ID: 19365143
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study.
    Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V, Minutoli L, Atteritano M, Levy RM, Frisina N, Mazzaferro S, Frisina A, D'Anna R, Cancellieri F, Cannata ML, Corrado F, Lubrano C, Marini R, Adamo EB, Squadrito F.
    Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):332-40. PubMed ID: 19631515
    [Abstract] [Full Text] [Related]

  • 12. The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis.
    Gurban CV, Mederle O.
    Rom J Morphol Embryol; 2011 Jun; 52(3 Suppl):1113-9. PubMed ID: 22119834
    [Abstract] [Full Text] [Related]

  • 13. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Jun; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 14. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO, Choi JT, Choi HA, Moon IG, Yim CH, Park WK, Yoon HK, Han IK.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [Abstract] [Full Text] [Related]

  • 15. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.
    Zhang G, Qin L, Shi Y.
    J Bone Miner Res; 2007 Jul; 22(7):1072-9. PubMed ID: 17419678
    [Abstract] [Full Text] [Related]

  • 16. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B.
    Arch Immunol Ther Exp (Warsz); 2005 Jul; 53(5):454-64. PubMed ID: 16314829
    [Abstract] [Full Text] [Related]

  • 17. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [Abstract] [Full Text] [Related]

  • 18. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P, Tauchmanova L, Risitano AM, Carella C, Mazziotti G, Lombardi G, Colao A, Rotoli B, Selleri C.
    Transplantation; 2006 Dec 15; 82(11):1449-56. PubMed ID: 17164716
    [Abstract] [Full Text] [Related]

  • 19. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, Pachman LM.
    Arthritis Rheum; 2007 Mar 15; 56(3):977-83. PubMed ID: 17328075
    [Abstract] [Full Text] [Related]

  • 20. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007 Mar 15; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.